Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

TAK-981, a First-in-Class SUMO-Activating Enzyme Inhibitor, Combined with Rituximab in Adult Patients (Pts) with CD20-Positive Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Phase 1 Data

Sarit Assouline, Amitkumar Mehta, Tycel Phillips, Lapo Alinari, Alexey V. Danilov, Stéphane Doucet, Steven I. Park, Deborah Berg, Alejandro Gomez-Pinillos, Alonzo Martinez, Bo Chao, Allison J Berger, John Gibbs, Sharon Friedlander, Christine K. Ward, Igor Proscurshim, Brenda W. Cooper, Paolo F Caimi

Blood (2021) 138 (Supplement 1): 2488.

https://doi.org/10.1182/blood-2021-152225

Published: 2021

Journal Articles

Entinostat, a Novel Histone Deacetylase (HiDAC) Inhibitor Is Active in B-Cell Lymphoma and Enhances the Anti-Tumor Activity of Rituximab, Chemotherapy Agents and Proteasome Inhibitors

Sarah Frys, BSc, Matthew J. Barth, MD, Cory Mavis, BSc, MSc, Juan Gu, PhD, John Gibbs, MD, Myron S. Czuczman, MD, Francisco Hernandez-Ilizaliturri, MD

Blood (2012) 120 (21): 1649.

https://doi.org/10.1182/blood.V120.21.1649.1649

Published: 2012

Journal Articles

Apoptotic and Non-Apoptotic Cellular Pathways Executed by Bortezomib (BTZ) in Rituximab-Resistant Lymphomas

Juan Gu, PhD, Francisco J. Hernandez-Ilizaliturri, MD, Cory Mavis, BSc, MSc, Natalie M Czuczman, Karen E Thudium, George Deeb, MD, John Gibbs, MD, Myron S. Czuczman, MD

Blood (2011) 118 (21): 4967.

https://doi.org/10.1182/blood.V118.21.4967.4967

Published: 2011

Journal Articles

Activity of Rituximab and Ofatumumab Against Mantle Cell Lymphoma (MCL) in Vitro in MCL Cell Lines and Ex Vivo in Tumor Cells Derived From Patient Tumor Samples

Matthew J. Barth, MD, Gopichand Pendurty, MD, Cory Mavis, BSc, MSc, Natalie M Czuczman, John Gibbs, MD, George Deeb, MD, Myron S. Czuczman, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2011) 118 (21): 4972.

https://doi.org/10.1182/blood.V118.21.4972.4972

Published: 2011

Journal Articles

Entinostat, a Novel Histone Deacetylase (HiDAC) Inhibitor Enhances the Anti-Tumor Activity of Bortezomib (BTZ) in Rituximab-Chemotherapy Sensitive and Resistant Lymphoma Cell Lines,

Cory Mavis, BSc, MSc, Sarah Frys, BSc, Juan Gu, PhD, John Gibbs, MD, Myron S. Czuczman, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2011) 118 (21): 3734.

https://doi.org/10.1182/blood.V118.21.3734.3734

Published: 2011

Journal Articles

Distinct molecular mechanisms responsible for bortezomib-induced death of therapy-resistant versus -sensitive B-NHL cells

Scott H. Olejniczak, Jennifer Blickwedehl, Alan Belicha-Villanueva, Naveen Bangia, Wasif Riaz, Cory Mavis, James L. Clements, John Gibbs, Francisco J. Hernandez-Ilizaliturri, Myron S. Czuczman

Blood (2010) 116 (25): 5605–5614.

https://doi.org/10.1182/blood-2009-12-259754

Published: 2010

Journal Articles

Ofatumumab, a Fully Human Monoclonal Antibody Targeting CD20, Demonstrates Activity Against and Potentiates the Anti-Tumor Activity of Chemotherapy Agents In Rituximab-Sensitive Cell Lines (RSCL), Rituximab-Resistant Cell Lines (RRCL), Lymphoma Xenografts, and Primary Tumor Cells Derived From Patients with B-Cell Non-Hodgkin Lymphoma (NHL)

Matthew Barth, MD, Francisco J. Hernandez-Ilizaliturri, MD, Cory Mavis, BSc, MSc, Ping-Chiao Tsai, John Gibbs, MD, George Deeb, MD, Myron S. Czuczman, MD

Blood (2010) 116 (21): 3917.

https://doi.org/10.1182/blood.V116.21.3917.3917

Published: 2010

Journal Articles

Panobinostat, a Novel Histone Deacetylase (HiDAC) Inhibitor Enhances the Anti-Tumor Activity of Bortezomib (BTZ) In Rituximab-Chemotherapy Sensitive and Resistant Lymphoma Cell Lines

Francisco J. Hernandez-Ilizaliturri, MD, Cory Mavis, BSc, MSc, Ilir Maraj, Mohammad Muhsin Chisti, John Gibbs, MD, Myron S. Czuczman, MD

Blood (2010) 116 (21): 3936.

https://doi.org/10.1182/blood.V116.21.3936.3936

Published: 2010

Journal Articles

MLN2238, a Novel and Potent Proteasome Inhibitor, Induces Caspase-Dependent Cell Death, Cell-Cycle Arrest, and Potentiates the Anti-Tumor Activity of Chemotherapy Agents In Rituximab-Chemotherapy Sensitive or Resistant B-Cell Lymphoma Cell Lines

Juan Gu, PhD, Patil Ritesh, MD, MPH, Cory Mavis, BSc, MSc, George Deeb, MD, John Gibbs, MD, Francisco J. Hernandez-Ilizaliturri, MD, Myron S. Czuczman, MD

Blood (2010) 116 (21): 3939.

https://doi.org/10.1182/blood.V116.21.3939.3939

Published: 2010

Journal Articles

Entinostat (SNDX-275), a Novel DAC Inhibitor, Is Highly Effective in Rituximab- [Chemotherapy]-Sensitive or Rituximab-[Chemotherapy]-Resistant Lymphomas and Has Synergistic Anti-Tumor Activity When Combined with Bortezomib.

Umeer Ashraf, MD, Myron S. Czuczman, MD, Cory Marvis, MS, John Gibbs, MD, Francisco J Hernandez-Ilizaliturri, MD

Blood (2009) 114 (22): 3727.

https://doi.org/10.1182/blood.V114.22.3727.3727

Published: 2009

Journal Articles

Obatoclax and Bortezomib Therapy Results in Disruption of the p53-Mediated Apoptosis/Autophagy Pathway and Is Associated with Potent Synergistic Anti-Tumor Activity against Rituximab-Chemotherapy-Sensitive and -Resistant B-Cell Lymphoma.

Francisco Hernandez-Ilizaliturri, MD, Ping-Chiao Tsio, MS, Ryan Campagna, BS, Cory Marvis, MS, Wasif Riaz, MD, Elizabeth Gruber, MS, John Gibbs, MD, Myron S. Czuczman, MD

Blood (2009) 114 (22): 288.

https://doi.org/10.1182/blood.V114.22.288.288

Published: 2009

Journal Articles

The DAC Inhibitor, LBH589, Is Highly Effective in Both Rituximab-Sensitive and Rituximab-Resistant Lymphomas and Enhances the Anti-Tumor Activity of Bortezomib, Other Chemotherapy Agents, and Anti-CD20 Monoclonal Antibodies.

Francisco J Hernandez-Ilizaliturri, MD, Cory Marvis, MS, Ilir Maraj, MD, Mohammad M Chisti, MD, John Gibbs, MD, Myron S Czuczman

Blood (2009) 114 (22): 2715.

https://doi.org/10.1182/blood.V114.22.2715.2715

Published: 2009

NARROW

TAK-981, a First-in-Class SUMO-Activating Enzyme Inhibitor, Combined with Rituximab in Adult Patients (Pts) with CD20-Positive Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Phase 1 Data

Entinostat, a Novel Histone Deacetylase (HiDAC) Inhibitor Is Active in B-Cell Lymphoma and Enhances the Anti-Tumor Activity of Rituximab, Chemotherapy Agents and Proteasome Inhibitors

Apoptotic and Non-Apoptotic Cellular Pathways Executed by Bortezomib (BTZ) in Rituximab-Resistant Lymphomas

Activity of Rituximab and Ofatumumab Against Mantle Cell Lymphoma (MCL) in Vitro in MCL Cell Lines and Ex Vivo in Tumor Cells Derived From Patient Tumor Samples

Entinostat, a Novel Histone Deacetylase (HiDAC) Inhibitor Enhances the Anti-Tumor Activity of Bortezomib (BTZ) in Rituximab-Chemotherapy Sensitive and Resistant Lymphoma Cell Lines,

Distinct molecular mechanisms responsible for bortezomib-induced death of therapy-resistant versus -sensitive B-NHL cells

Panobinostat, a Novel Histone Deacetylase (HiDAC) Inhibitor Enhances the Anti-Tumor Activity of Bortezomib (BTZ) In Rituximab-Chemotherapy Sensitive and Resistant Lymphoma Cell Lines

MLN2238, a Novel and Potent Proteasome Inhibitor, Induces Caspase-Dependent Cell Death, Cell-Cycle Arrest, and Potentiates the Anti-Tumor Activity of Chemotherapy Agents In Rituximab-Chemotherapy Sensitive or Resistant B-Cell Lymphoma Cell Lines

Entinostat (SNDX-275), a Novel DAC Inhibitor, Is Highly Effective in Rituximab- [Chemotherapy]-Sensitive or Rituximab-[Chemotherapy]-Resistant Lymphomas and Has Synergistic Anti-Tumor Activity When Combined with Bortezomib.

Obatoclax and Bortezomib Therapy Results in Disruption of the p53-Mediated Apoptosis/Autophagy Pathway and Is Associated with Potent Synergistic Anti-Tumor Activity against Rituximab-Chemotherapy-Sensitive and -Resistant B-Cell Lymphoma.

The DAC Inhibitor, LBH589, Is Highly Effective in Both Rituximab-Sensitive and Rituximab-Resistant Lymphomas and Enhances the Anti-Tumor Activity of Bortezomib, Other Chemotherapy Agents, and Anti-CD20 Monoclonal Antibodies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only